Abstract
The targeted delivery of theranostic agents to the cancer cells is one of the major challenges and an active field of research in the development of cancer chemotherapeutic approaches. Theranostic metallic nanoparticles (TMNPs) have garnered increasing attention in recent years as a novel tool for theranostic application such as imaging, diagnosis, and therapeutic delivery of active agents to tumour specific cells. This paper attempts to unveil the multidimensional theranostic aspects of multifunctional metallic nanoparticles (MNPs) including passive and active targeting (HER2, Folate, Angiogenesis etc.) as well as the RES escaping approach. Special attention is given to the theranostic application of MNPs in oncology. Patents issued by the US office in this nanotechnological arena are also included emphasising the importance of MNPs in current cancer treatment/imaging research scenario. Keeping in mind the blooming research in clinical application directed nanotechnology; toxicity concerns related with MNPs are. also discussed, in element.
Keywords: Metallic nanoparticles (MNPs), Active and passive targeting, Patents, Theranostic application, Quantum dots, Toxicity assessment, Toxicity, Metallic nanoparticles, Abraxan, Doxil, tumours, electrostatic, diagnostic, theranostic, oncological, mononuclear, phagocyte, zeta potential
Current Pharmaceutical Design
Title: Cancer Targeted Metallic Nanoparticle: Targeting Overview, Recent Advancement and Toxicity Concern
Volume: 17 Issue: 18
Author(s): Sohail Akhter, Mohammad Zaki Ahmad, Anjali Singh, Iqbal Ahmad, Mahfoozur Rahman, Mohammad Anwar, Gaurav Kumar Jain, Farhan Jalees Ahmad and Roop Krishen Khar
Affiliation:
Keywords: Metallic nanoparticles (MNPs), Active and passive targeting, Patents, Theranostic application, Quantum dots, Toxicity assessment, Toxicity, Metallic nanoparticles, Abraxan, Doxil, tumours, electrostatic, diagnostic, theranostic, oncological, mononuclear, phagocyte, zeta potential
Abstract: The targeted delivery of theranostic agents to the cancer cells is one of the major challenges and an active field of research in the development of cancer chemotherapeutic approaches. Theranostic metallic nanoparticles (TMNPs) have garnered increasing attention in recent years as a novel tool for theranostic application such as imaging, diagnosis, and therapeutic delivery of active agents to tumour specific cells. This paper attempts to unveil the multidimensional theranostic aspects of multifunctional metallic nanoparticles (MNPs) including passive and active targeting (HER2, Folate, Angiogenesis etc.) as well as the RES escaping approach. Special attention is given to the theranostic application of MNPs in oncology. Patents issued by the US office in this nanotechnological arena are also included emphasising the importance of MNPs in current cancer treatment/imaging research scenario. Keeping in mind the blooming research in clinical application directed nanotechnology; toxicity concerns related with MNPs are. also discussed, in element.
Export Options
About this article
Cite this article as:
Akhter Sohail, Zaki Ahmad Mohammad, Singh Anjali, Ahmad Iqbal, Rahman Mahfoozur, Anwar Mohammad, Kumar Jain Gaurav, Jalees Ahmad Farhan and Krishen Khar Roop, Cancer Targeted Metallic Nanoparticle: Targeting Overview, Recent Advancement and Toxicity Concern, Current Pharmaceutical Design 2011; 17 (18) . https://dx.doi.org/10.2174/138161211796391001
DOI https://dx.doi.org/10.2174/138161211796391001 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements